PBYI vs. AUTL, ERAS, ORIC, VECT, TECX, KURA, CRGX, HUMA, PHVS, and ANNX
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Autolus Therapeutics (AUTL), Erasca (ERAS), ORIC Pharmaceuticals (ORIC), VectivBio (VECT), Tectonic Therapeutic (TECX), Kura Oncology (KURA), CARGO Therapeutics (CRGX), Humacyte (HUMA), Pharvaris (PHVS), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.
Puma Biotechnology vs.
Autolus Therapeutics (NASDAQ:AUTL) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.
In the previous week, Autolus Therapeutics had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 10 mentions for Autolus Therapeutics and 4 mentions for Puma Biotechnology. Autolus Therapeutics' average media sentiment score of 0.44 beat Puma Biotechnology's score of -0.10 indicating that Autolus Therapeutics is being referred to more favorably in the media.
72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Autolus Therapeutics presently has a consensus price target of $10.40, suggesting a potential upside of 368.47%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 135.69%. Given Autolus Therapeutics' higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Puma Biotechnology.
Puma Biotechnology has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Puma Biotechnology has a net margin of 9.56% compared to Autolus Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Autolus Therapeutics' return on equity.
Puma Biotechnology received 324 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 67.96% of users gave Autolus Therapeutics an outperform vote while only 67.11% of users gave Puma Biotechnology an outperform vote.
Autolus Therapeutics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Summary
Autolus Therapeutics beats Puma Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:PBYI) was last updated on 1/20/2025 by MarketBeat.com Staff
